

50454-56101USCIP3

09/470,603

Eugenio Cefali

31 October 1997

1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

1	<b>Expert Report of Cheryl D. Blume, Ph.D. (January 27, 2004)</b> - Subject to Protective Order
2	<b>Expert Report of Dr. Sergio Fazio (February 4, 2004) [Redacted Version]</b> - Subject to Protective Order
3	<b>Rebuttal Expert Report of Dr. Sergio Fazio (April 2, 2004)</b> - Subject to Protective Order
4	<b>Expert Report of Dr. Sergio Fazio Regarding U.S. Patent No. 6,676,967 (August 17, 2004)</b> - Subject to Protective Order
5	<b>Expert Report of Don W. Martens (February 6, 2004) [Redacted Version]</b> - Subject to Protective Order
6	<b>Expert Report of Don W. Martens Regarding U.S. Patent No. 6,676,967 (August 20, 2004) [Redacted Version]</b> - Subject to Protective Order
7	<b>Expert Report of Dr. Joseph R. Robinson (February 5, 2004) [Redacted Version]</b> - Subject to Protective Order
8	<b>Expert Report of Dr. Joseph R. Robinson Regarding U.S. Patent No. 6,676,967 (August 18, 2004)</b> - Subject to Protective Order
9	<b>Rebuttal Expert Report of Thomas S. Foster, Pharm.D. (April 2, 2004)</b> - Subject to Protective Order

	<b>10</b>	<b>Rebuttal Expert Report of Thomas S. Foster, Pharm.D. Regarding The '967 Patent (October 4, 2004) - Subject to Protective Order</b>
	<b>11</b>	<b>Rebuttal Expert Report of James W. McGinity, Ph.D. (April 2, 2004) - Subject to Protective Order</b>
	<b>12</b>	<b>Supplemental Rebuttal Expert Report of James W. McGinity, Ph.D. (August 18, 2004) - Subject to Protective Order</b>
	<b>13</b>	<b>Rebuttal Expert Report of James W. McGinity, Ph.D. Regarding The '967 Patent (September 30, 2004) - Subject to Protective Order</b>
	<b>14</b>	<b>Expert Report of Mark E. McGovern, M.D. (February 6, 2004) - Subject to Protective Order</b>
	<b>15</b>	<b>Expert Report of Mark E. McGovern, M.D. (August 20, 2004) - Subject to Protective Order</b>
	<b>16</b>	<b>Expert Report of Frank M. Sacks, M.D. (April 2, 2004) - Subject to Protective Order</b>
	<b>17</b>	<b>Expert Report of Frank M. Sacks, M.D. (August 20, 2004) - Subject to Protective Order</b>
	<b>18</b>	<b>Rebuttal Expert Report of Mary Ann Tucker, Esq. (April 2, 2004) - Subject to Protective Order</b>
	<b>19</b>	<b>Rebuttal Expert Report of Mary Ann Tucker, Esq. Regarding The '967 Patent (October 1, 2004) - Subject to Protective Order</b>
	<b>20</b>	<b>Carl J. Lavie, et al., <i>Marked Benefit with Sustained-Release Niacin Therapy in Patients with Alisolated@ Very Low Levels of High-Density Lipoprotein Cholesterol and Coronary Artery Disease</i>, Am. J. Cardiol. 1992;69:1083-1085</b>
	<b>21</b>	<b>Excerpts from the 1993, 2000, and 2002 editions of the Physician's Desk Reference</b>
	<b>22</b>	<b><i>Niacin: Double-edged Sword for Lowering Cholesterol</i>, Tufts University Diet &amp; Nutritional Letter (Tufts Univ., Boston, MA), August 1994, Vol. 12, issue 6</b>
	<b>23</b>	<b>Larsen, ML and Illingworth, DR, <i>Drug Treatment of Dyslipoproteinemia</i>, Med Clin N Am., 78:225-245 (1994)</b>
	<b>24</b>	<b>Lavie, Letter to Editor, JAMA 1994; 272:513-515</b>

	25	Keenan, Letter to Editor, JAMA 1994; 272:513-515
	26	Shields & Beckmann, Letter to Editor, JAMA 1994; 272:513-515
	27	Thomas N. Tozer, Clinical Pharmacokinetics Concepts and Applications (3d ed. 1995) at Chapter 9, p. 120
	28	Excerpts from the United States Pharmacopeia (1995)
	29	Morgan & Capuzzi Abstract, <i>Safe and Effective Treatment of Dyslipidemia by Niaspan, a New Sustained-Release Niacin</i> , Clinical Pharmacology & Therapeutics (February 1996)
	30	Morgan & Capuzzi Article, <i>Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial</i> , J. Cardiovasc. Pharmacol. Therapeut. 1(3):195-202 (July 1996)
	31	Capuzzi DM, et al., <i>Efficacy and Safety of An Extended-Release Niacin (Niaspan): A Long-Term Study</i> , Am J Cardiol. 1998;82:74U-81U
	32	Guyton JR, <i>Advances in Dyslipidemia: Discussion Session II</i> , Am J Cardiol, 1998: 82(12A): 85U-86U
	33	Knopp RH, et al., <i>Equivalent Efficacy of a Time-Release Form of Niacin (Niaspan) Given Once-a-Night Versus Plain Niacin in the Management of Hyperlipidemia</i> , Metabolism 47:1097-1104 (1998)
	34	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 21:179-182, 1998
	35	Elam MB, et al., <i>Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease</i> , JAMA: 2000; 284:1263-1270
	36	Kesala R, et al., <i>Niacin (N) vs. Niaspan (NS) Treatment of the Atherogenic Lipid Profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in Diabetic Patients (DP)</i> , Diabetes 49 (suppl. 1): A268 at 1114-P (June 2000)
	37	2001 NCEP Report at VI-11, Table VI.2-3
	38	Wang, W. et al., <i>Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production</i> , Am J Physiol Endocrinol Metab., 280:E540-E547 (2001)

	39	<b>Smith SC, et al., AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update. AHA/ACC Scientific Statement, 1577-79</b>
	40	<b>Tavintharan S and Kashyap M, The Benefits of Niacin in Atherosclerosis, Curr Athero. Reports 2001; 3:74-82</b>
	41	<b>Meadows M., Serious Liver Injury: Leading Reason for Drug Removals, Restrictions, FDA Consumer Magazone, May-June 2001; <a href="http://www.fda.gov/fdac/features/2001/301_liver.html">http://www.fda.gov/fdac/features/2001/301_liver.html</a></b>
	42	<b>Grundy SM, et al., Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 Diabetes. Arch Intern Med. 2002; 162: 1568-1576</b>
	43	<b>American Diabetes Association: Management of Dyslipidemia in Adults with Diabetes, Diabetes Care 25:S74-S77, 2002</b>
	44	<b>Pan J, et al., Niacin Treatment of the Atherogenic Lipid Profile and Lp(a) in Diabetes, Diabetes, Obesity and Metabolism 4:255-261 (2002)</b>
	45	<b>Pan J, et al., Extended-Release Niacin Treatment of the Atherogenic Lipid Profile and Lipoprotein(a) in Diabetes, Metabolism 51:1120-1127 (2002)</b>
	46	<b>Meyers CD, et al., Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia, Ann Intern Med. 2003; 139:996-1002</b>
	47	<b>CDER Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations (March 2003)</b>
	48	<b>American Diabetes Association: Dyslipidemia Management in Adults with Diabetes, Diabetes Care 27:S68-S71, 2004</b>
	49	<b>Sample Kos Clinical Trial Medical Consent Form - Subject to Protective Order</b>
	50	<b>Sample Kos Clinical Trial Investigator's Statement - Subject to Protective Order</b>

EXAMINER

DATE CONSIDERED